U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07251309) titled 'A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia' on Nov. 18.
Brief Summary: This clinical trial consists of 2 parts, Part A and Part B. Part A consists of a 2-day randomized, double-blind, placebo-controlled corrective phase (CP) and a 28-day randomized, double-blind, placebo-controlled maintenance phase (MP). Part B (open-label extension, OLE) is an open-label, 11-month extension study carried out in participants who come from Part A and meet certain inclusion criteria.
Study Start Date: Dec. 23, 2024
Study Type: INTERVENTIONAL
Condition:
Hyperkalemia
Intervention:
DRUG:...